Data / Form D filings / Helocyte, Inc.
Helocyte, Inc.: Form D filings
Helocyte, Inc., a biotechnology company in New York, NY, filed 3 Form D notices with the SEC in 2016. The latest, on November 4, 2016, reports $4 million sold of a $5 million offering to 61 investors.
Find out what Helocyte, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2 GANSEVOORT STREET, 9TH FLOOR, New York, NY, 10014
- Phone
- (212) 554-4520
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2015
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1679808
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2016 | Amendment | $5,000,000 | $3,998,000 | $1,002,000 | 61 | Oct 31, 2016 | sec.gov |
| Oct 14, 2016 | Amendment | $5,000,000 | $3,018,000 | $1,982,000 | 34 | Sep 30, 2016 | sec.gov |
| Jul 15, 2016 | New notice | $5,000,000 | $1,000,000 | $4,000,000 | 11 | Jun 30, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kenneth W. Cappell | Director | |
| Elizabeth Clark Moore | Executive Officer | |
| David J. Horin | Executive Officer | |
| Lindsay A. Rosenwald | Director | |
| Michael S. Weiss | Director | |
| Frank Taffy | Executive Officer, Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Oct 31, 2016 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Helocyte, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.